Upsher-Smith Laboratories, Inc. has entered into an exclusive agreement with Pharmathen S.A. to develop and distribute a generic product in a market category with U.S. sales of more than $500 million (IMS Health, 12 months ending in July 2016). This new collaboration illustrates Upsher-Smith's ongoing interest in building strategic relationships to grow its generic product pipeline.
Under the terms of the agreement, Pharmathen will develop, manufacture and supply the product. Upsher-Smith will submit the ANDA, market and distribute the product exclusively in the United States as a generic under the Upsher-Smith label. Financial terms have not been disclosed.
"Upsher-Smith is pleased to collaborate with Pharmathen, one of the fastest growing generic companies in Europe," said Rusty Field, President, Upsher-Smith. "Our commitment to quality and cost-effective products, coupled with the highest level of customer support, has helped make Upsher-Smith a trusted partner in the U.S. generics marketplace."